Entero Therapeutics, Inc. (ENTO)
ENTO Stock Price Chart
Explore Entero Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ENTO price movements and trends.
ENTO Company Profile
Discover essential business fundamentals and corporate details for Entero Therapeutics, Inc. (ENTO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Oct 2016
Employees
2.00
Website
https://www.firstwavebio.comCEO
Richard Joel Paolone
Description
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
ENTO Financial Timeline
Browse a chronological timeline of Entero Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 11 Nov 2025
Stock split effective on 18 Aug 2025
Shares were split 1 : 3 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Aug 2025
EPS came in at -$0.14 .
Earnings released on 15 May 2025
EPS came in at -$0.63 .
Earnings released on 4 Apr 2025
EPS came in at -$2.61 falling short of the estimated -$0.41 by -536.59%.
Earnings released on 13 Nov 2024
EPS came in at -$1.32 falling short of the estimated -$0.96 by -37.50%.
Earnings released on 26 Aug 2024
EPS came in at -$3.84 falling short of the estimated -$1.55 by -147.68%.
Earnings released on 14 May 2024
EPS came in at $0.38 surpassing the estimated -$2.43 by +115.64%.
Earnings released on 27 Feb 2024
EPS came in at -$5.35 falling short of the estimated -$4.03 by -32.75%.
Stock split effective on 18 Dec 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2023
EPS came in at -$9.08 surpassing the estimated -$33.60 by +72.98%.
Earnings released on 30 Jun 2023
EPS came in at -$36.89 falling short of the estimated -$20.80 by -77.38%.
Earnings released on 31 Mar 2023
EPS came in at -$35.70 surpassing the estimated -$43.90 by +18.69%.
Stock split effective on 18 Jan 2023
Shares were split 1 : 7 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Dec 2022
EPS came in at -$80.12 .
Earnings released on 30 Sept 2022
EPS came in at $378.17 surpassing the estimated -$421.40 by +189.74%.
Stock split effective on 26 Aug 2022
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Jun 2022
EPS came in at -$1.04K surpassing the estimated -$2.10K by +50.40%.
Earnings released on 31 Mar 2022
EPS came in at -$2.60K .
Earnings released on 31 Dec 2021
EPS came in at -$3.16K .
Earnings released on 30 Sept 2021
EPS came in at -$13.67K .
Stock split effective on 13 Sept 2021
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Jun 2021
EPS came in at -$4.99K .
Earnings released on 31 Mar 2021
EPS came in at -$5.83K .
Earnings released on 31 Dec 2020
EPS came in at -$24.98K .
Earnings released on 30 Sept 2020
EPS came in at -$7.83K .
ENTO Stock Performance
Access detailed ENTO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.